Hua Teng Pharmaceutical Closed on 50 Million Yuan Series A Financing

According to Lieyunwang, Hunan Hua Teng Pharmaceutical Co, Ltd. (Hua Teng Pharmaceutical) announced the completion of 50 million yuan Series A financing, led by Tasly Capital, Zhuhai Danchi Equity Investment and Hunan Dingteng Juzhi Investment Partnership. This round of financing will be mainly used for the construction of the healthcare industrial park, the commercialization of long-acting slow-release targeted drugs and the promotion of PEG-drug technology.

Founded in August 2013 by Dr. Deng Zeping, Hua Teng Pharmaceutical is dedicated to the R&D and production of biological products and carrying out targeting antineoplastic drugs R&D of high-tech enterprises. The company has developed and produced thousands of products, including large and small PEG derivatives, biochemical reagents, pharmaceutical intermediates, APIs and targeted anti-tumor drugs.

Hua Teng Pharmaceutical has its own logistics centers in China, Europe and the United States and other countries, and has established an excellent and efficient R&D and sales team. The company accurately provides customers around the world with professional, personalized one-stop service. 

"This round of financing will further improve the development of Hua Teng Pharmaceutical and the development of the pharmaceutical industry in Hunan,” said Deng Zeping, the chairman of Hua Teng Pharmaceutical.

As a wholly-owned subsidiary of Tasly Holding Group, Tasly Capital Holding (Beijing) Co., LTD (Tasly Capital) mainly invests in mature enterprises in the field of healthcare.